Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients
Effects of ADXS-PSA With or Without Pembrolizumab on Survival and Antigen Spreading in Metastatic, Castration-Resistant Prostate Cancer Patients (Results from KEYNOTE-046)
AACR2019-keynote-046-adxs-psa-plus-pembrolizumab-metastatic-castration-resistant-prostate-cancer
AACR2019-adxs-neo-safety-and-immunogenicity-of-a-personalized-neoantigen
KEYNOTE-046 AACR 2019 Abstract
ADXS-NEO AACR 2019 Abstract
KEYNOTE-046: ADXS-PSA Plus Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
Targeting shared hotspot cancer mutations with a Listeria monocytogenes immunotherapy induce potent anti-tumor immunity
Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a Listeria-based immunotherapy platform
Targeting frameshift mutations with a Listeria monocytogenes immunotherapy drives neoantigen-specific anti-tumor immunity in the MC38 and CT26 mouse tumor models
Targeting of CCR8 induces antitumor activity as a monotherapy that is further enhanced in combination with a Listeria-based immunotherapy
Combination TIGIT blockade with Listeria-based immunotherapy enhances antigen-specific antitumor immunity
Agonism of the CD137 co-stimulatory pathway synergizes with the Listeria monocytogenes-based immunotherapy, axalimogene filolisbac, to promote durable tumor regression in a murine HPV+ tumor model
Immunotherapy: A New Strategy for the Treatment of Cervical Cancer
Tolerability of ADXS11-001 Lm-LLO Listeria Based Immunotherapy With Mitomycin, Fluorouracil and Radiation for Anal Cancer
